.png){kind=icon}
.png){kind=icon}
Return
Acquired platelet function disorders
.png){kind=icon}
PRE
AI
DOI：10.1016/j.thromres.2019.06.009.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The possibility of an acquired platelet function disorder should be considered in patients who present with recent onset muco-cutaneous bleeding. Despite the availability of newer and faster platelet function assays, light transmission aggregometry (LTA) remains the preferred diagnostic test. This review examines and discusses the causes of acquired platelet dysfunction; most commonly drugs, dietary factors, medical disorders and procedures. In addition to well-known antiplatelet therapies, clinicians should be alert for newer drugs which can affect platelets, such as ibrutinib. There is little clinical trial evidence to guide the management of acquired platelet function defects, but we summarise commonly employed strategies, which include addressing the underlying cause, antifibrinolytic agents, desmopressin infusions, and in selected patients, platelet transfusions.
Keywords:
SEROTONIN REUPTAKE INHIBITORS
SELECTIVE SEROTONIN
GLANZMANNS-THROMBASTHENIA
CARDIOPULMONARY BYPASS
ANTIPLATELET COMPOUND
FUNCTION ANALYZER
GAUCHER-DISEASE
HIGH-SHEAR
DYSFUNCTION
ACTIVATION
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
3.4
Papers:
1.1W
Citations:
1.3W